Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential
Diseases · 23.09.2024 · 12 (9) · 226
DOI: 10.3390/diseases12090226 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diseases, online erschienen am 23.09.2024. Verfasst von Anastasia V Poznyak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Atherosclerosis Research, Osennyaya 4-1-207, 121609 Moscow, Russia. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by the presence of various serum autoantibodies and multi-system effects, predominantly affecting young female patients. The pathogenesis of SLE involves a combination of genetic factors, environmental triggers, and pathogen invasions that disrupt immune cell activation, leading to the release of autoantibodies and chronic inflammation. Mitochondria, as the primary cellular powerhouses, play a crucial role in SLE development through their control of energy generation, reactive oxygen species (ROS) production, and cellular apoptotic pathways. Dysregulation of mitochondrial structure and function can contribute to the immune dysregulation, oxidative stress, and inflammation seen in SLE. Recent research has highlighted the impact of mitochondrial dysfunction on various immune cells involved in SLE pathogenesis, such as T-lymphocytes, B-lymphocytes, neutrophils, and plasmacytoid dendritic cells. Mitochondrial dysfunction in these immune cells leads to increased ROS production, disrupted mitophagy, and alterations in energy metabolism, contributing to immune dysregulation and inflammation. Moreover, genetic variations in mitochondrial DNA (mtDNA) and abnormalities in mitochondrial dynamics have been linked to the pathogenesis of SLE, exacerbating oxidative stress and immune abnormalities. Targeting mitochondrial function has emerged as a promising therapeutic approach for SLE. Drugs such as sirolimus, N-acetylcysteine, coenzyme Q10, and metformin have shown potential in restoring mitochondrial homeostasis, reducing oxidative stress, and modulating immune responses in SLE. These agents have demonstrated efficacy in preclinical models and clinical studies by improving disease activity, reducing autoantibody titers, and ameliorating organ damage in SLE patients. In conclusion, this review underscores the critical role of mitochondria in the pathogenesis of SLE and the potential of targeting mitochondrial dysfunction as a novel therapeutic strategy for improving outcomes in SLE patients. Further investigation into the mechanisms underlying mitochondrial involvement in SLE and the development of targeted mitochondrial therapies hold promise for advancing SLE treatment and enhancing patient care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Atherosclerosis Research, Osennyaya 4-1-207, 121609 Moscow, Russia.
- Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 8 Baltiiskaya Street, 125315 Moscow, Russia.
- Russian Gerontology Clinical Research Centre, Institute on Aging Research, Pirogov Russian National Research Medical University, Russian Federation, 16 1st Leonova Street, 129226 Moscow, Russia.
- Department of Polyclinic Therapy, N.N. Burdenko Voronezh State Medical University, 10 Studencheskaya Street, 394036 Voronezh, Russia.
- Vascular Surgery Department, A.V. Vishnevsky National Medical Research Center of Surgery, 27 Bolshaya Serpukhovskaya Street, 117997 Moscow, Russia.
ORCID-Profile: Anastasia V Poznyak, Alexey V Churov, Irina A Starodubtseva, Dmitry F Beloyartsev, Vasily N Sukhorukov, Alexander N Orekhov
Förderung
- Russian Science Foundation
Zitieren
APA
Poznyak, A. V., Orekhov, N. A., Churov, A. V., Starodubtseva, I. A., Beloyartsev, D. F., Kovyanova, T. I., Sukhorukov, V. N., & Orekhov, A. N. (2024). Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential. Diseases, 12(9), 226. https://doi.org/10.3390/diseases12090226
Vancouver
Poznyak AV, Orekhov NA, Churov AV, Starodubtseva IA, Beloyartsev DF, Kovyanova TI, et al. Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential. Diseases. 2024;12(9):226. doi:10.3390/diseases12090226
BibTeX
@article{Poznyak2024,
author = {Poznyak, Anastasia V and Orekhov, Nikolay A and Churov, Alexey V and Starodubtseva, Irina A and Beloyartsev, Dmitry F and Kovyanova, Tatiana I and Sukhorukov, Vasily N and Orekhov, Alexander N},
title = {Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential},
journal = {Diseases},
year = {2024},
volume = {12},
number = {9},
pages = {226},
doi = {10.3390/diseases12090226}
}
EUVIMED